Glenmark launches Olanzapine for Injection in USA

Glenmark launches Olanzapine for Injection in USA — Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, a single-dose vial. The product is indicated for schizophrenia and bipolar disorder. This launch expands Glenmark’s presence in the U.S. generics market. 📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ProductLaunch